Radiofrequency (RF) skin treatment devices and methods are provided herein. RF energy is delivered via electrodes in a phase-controlled manner which heats skin volumes below the surface more than the skin surface itself. At least one electrode at least partially encloses at least one other electrode. The combination of controlling the phases of the RF energy delivered to different electrodes and the enclosing configuration of the electrodes allows concentrating the delivered energy in specific regions below the skin surface at a particularly high efficiency. Configurations of the enclosing and the enclosed electrodes, their forms and combinations with other electrodes and the phase polarities applied to the electrodes are also provided.

One embodiment provides a tightly targeted minimally invasive therapy (TTMIT) parathyroid tissue ablating instrument. A substance that cytotoxically ablates parathyroidal tissue during application in the parathyroidal tissue of therapeutically sufficient units of an electromagnetic energy having a frequency only ranging from ultraviolet to visible to near infrared. A substance delivery device is configured to introduce the substance into the parathyroidal tissue. An electromagnetic energy treatment device is configured to apply the therapeutically sufficient units of the electromagnetic energy within a thermal range that is non-cytotoxic to the parathyroidal tissue to the substance after the substance has been introduced by the substance delivery device. A sensor is configured to monitor activation of the substance as the therapeutically sufficient units of the electromagnetic energy are applied. The electromagnetic energy treatment device is further configured to modulate applying the therapeutically sufficient units of the electromagnetic energy once the substance has been activated.

One embodiment provides a tightly targeted minimally invasive therapy (TTMIT) parathyroid tissue ablating instrument. A substance that cytotoxically ablates parathyroidal tissue during application in the parathyroidal tissue of therapeutically sufficient units of an electromagnetic energy having a frequency only ranging from ultraviolet to visible to near infrared. A substance delivery device is configured to introduce the substance into the parathyroidal tissue. An electromagnetic energy treatment device is configured to apply the therapeutically sufficient units of the electromagnetic energy within a thermal range that is non-cytotoxic to the parathyroidal tissue to the substance after the substance has been introduced by the substance delivery device. A sensor is configured to monitor activation of the substance as the therapeutically sufficient units of the electromagnetic energy are applied. The electromagnetic energy treatment device is further configured to modulate applying the therapeutically sufficient units of the electromagnetic energy once the substance has been activated.

A noninvasive system for imaging, planning, and treating cardiac arrhythmia in a subject includes a noninvasive means for imaging a heart and identifying an arrhythmia including an array of body surface electrodes for noninvasively measuring electrical potentials at a plurality of locations to identify the arrhythmia, and a geometry determining device for noninvasively obtaining a heart-torso geometry. An imaging processor computes heart electrical activity data and generates an image of the heart from the electrical potentials and the heart-torso geometry. A treatment planning system for developing a noninvasive treatment plan for the arrhythmia is configured to import an arrhythmia target defined relative to the image of the heart, and register the imported arrhythmia target to a primary planning dataset. A noninvasive means for treating the arrhythmia includes implementing the noninvasive treatment plan developed by the treatment planning system.

[Summary]

[Problem]

The therapy method and the therapy apparatus for difficult cancer such as ductal cancer and other diseases.

[Solution to problem]

The therapy and the apparatus to beat cancer and other diseases by injecting the material which is energy receptive from outside and emissive heat to cancer cells in the body of a patient, and giving energy from outside.

A biological measurement apparatus of this invention includes (i) a micro piezoelectric element for vibrating a nerve cell of a subject without coming in contact with the nerve cell, (ii) an electromagnetic wave antenna for receiving an electromagnetic wave generated by the nerve cell vibrated by the micro piezoelectric element, and (iii) a computer for measuring an electric charge of the nerve cell based on the electromagnetic wave received by the electromagnetic wave antenna. Further, this biological measurement apparatus includes an electromagnetic wave antenna for emitting an electromagnetic wave to a nerve cell. This configuration provides an apparatus capable of measuring an electrical activity of a nerve cell in a living organism in real time and three-dimensionally at a spatial resolution of a nerve cell size. Moreover, this configuration provides an apparatus capable of individually giving electrical stimulations to any desired cells in the subject.

A biological measurement apparatus of this invention includes (i) a micro piezoelectric element for vibrating a nerve cell of a subject without coming in contact with the nerve cell, (ii) an electromagnetic wave antenna for receiving an electromagnetic wave generated by the nerve cell vibrated by the micro piezoelectric element, and (iii) a computer for measuring an electric charge of the nerve cell based on the electromagnetic wave received by the electromagnetic wave antenna. Further, this biological measurement apparatus includes an electromagnetic wave antenna for emitting an electromagnetic wave to a nerve cell. This configuration provides an apparatus capable of measuring an electrical activity of a nerve cell in a living organism in real time and three-dimensionally at a spatial resolution of a nerve cell size. Moreover, this configuration provides an apparatus capable of individually giving electrical stimulations to any desired cells in the subject.

This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.

This invention relates to a method of diagnosing a subject as having and/or being a carrier for infantile myofibromatosis. This method involves providing an isolated biological sample from a subject; contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in PDGFRB and/or NOTCH3; detecting, in the sample, the presence or absence of the one or more mutations in PDGFRB and/or NOTCH3 based on said contacting; and diagnosing the subject as having and/or being a carrier for infantile myofibromatosis based on said detecting, where the presence of the one or more mutations in PDGFRB and/or NOTCH3 indicates the subject has a mutation that causes infantile myofibromatosis. Also disclosed is a method of treating a subject having infantile myofibromatosis and a method of preventing or treating symptoms associated with infantile myofibromatosis.

Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.